StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) company profile

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.78−0.16 (-1.61%)

Close on Nov 17, 2026Market cap $561.73MP/E –Yield –

About Climb Bio

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biotechnology business that develops therapies for individuals suffering from immune-mediated conditions. Its pipeline centers on two investigational monoclonal antibodies obtained through acquisitions and licensing: budoprutug and CLYM116. Budoprutug targets CD19 to deplete B cells in conditions such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 targets APRIL to suppress antibody production in immunoglobulin A nephropathy and related disorders. The company's end users are patients with serious autoimmune and inflammatory diseases.

The company conducts clinical development programs across several continents. It maintains or prepares trial sites in the United States, Australia, China, Argentina, Brazil, Georgia, Taiwan, Bulgaria, Greece, Serbia, Spain, Romania, and Ukraine. Additionally, it collaborates with a development partner located in China. The provided text does not disclose the location of the company's headquarters or its physical facilities.

Summary of the business section of Climb Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Climb Bio, Inc.
Headquarters
Wellesley Hills, MA
Address
20 William Street, Suite G50
Phone
1-866-857-2596
Employees
28, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Seattle, Washington

Stock & identifiers

Ticker
CLYM
Former tickers
ELYM until Oct 2, 2024
Exchange
Nasdaq
IPO date
Aug 11, 2021
Shares outstanding
57M, Jul 31, 2026
Public float
$44.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1768446
CUSIP
28658R106
ISIN
US28658R1068
FIGI
BBG00ZNKL0K6
Share class FIGI
BBG00ZNKL0L5
EIN
83-2273741

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Aoife BrennanPresident and CEO, Director87,731
Susan ALTSCHULLERChief Financial Officer–
Perrin Megan WilsonChief Business Officer–
Cindy DriscollSenior Vice President, Finance–
Emily PimblettSVP, Finance & CAO18,888
Brett KaplanChief Operating Officer–
RA Capital Nexus Fund II, L.P.Director288,461
Capital Healthcare Fund LP RADirector3,403,429
Rajeev M. ShahDirector–
RA Capital Nexus Fund III, L.P.Director–
Peter KolchinskyDirector3,396,318
RA Capital Nexus Fund, L.P.Director20,000
Ra Capital Management, L.P.Director–
Stephen Basil ThomasDirector467,969
Breanna Maurine CelebiDirector–
Andrew David LevinDirector0
Douglas E. WilliamsDirector–
Alexander CumboDirector–
Kimberlee C. DrapkinDirector–
Judith DunnDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Aoife Brennan, M.B., Ch B.
President and Chief Executive Officer
$669.50K$1.83M$405.05K$14.00K$2.92M-51%
Susan Altschuller, Ph.D., MBA
Chief Financial Officer (6)
$127.50K$963.06K$56.56K$4.25K$1.15M–
Perrin Wilson, Ph.D.
Chief Business Officer (8)
$406.88K$794.40K$228.26K$107.83K$1.54M–
Brett Kaplan, M.D.
Former Chief Operating Officer (11)
$223.61K$797.25K–$140.87K$1.16M-61%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 11, 2021
Offer price
$12.50
Securities offered
6,400,000
Gross proceeds
$80.00M
Exchange
Nasdaq
First trading day
Aug 10, 2021
First-day close
$15.90+27.2%
Lock-up ends (est.)
Feb 6, 2022

“The initial public offering price is $12.50 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 28 full-time employees, and one part-time employee, including a total of six employees with M.D., Ph.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 20, 2024Name changeName changed from Eliem Therapeutics, Inc. to Climb Bio, Inc.
Jun 27, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 4, 2024Merger voteDefinitive merger proxy statement
Aug 11, 2021IPOInitial public offering priced (424B4 prospectus)
Aug 3, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?